Fiehn, Christoph
Zinke, Silke
Haas, Jennifer S.
Meise, Dominic
Theil, Julia
Gurrath, Margot
Orzechowski, Hans-Dieter
Article History
Accepted: 28 December 2022
First Online: 9 February 2023
Declarations
:
: C. Fiehn has received consulting fees from AbbVie, Ablynx, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, MSD, Medac, Novartis, Pfizer, Roche, Sanofi, and UCB. S. Zinke has been an investigator for clinical trials for or received lecture or consulting fees from AbbVie, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB. J.S. Haas, D. Meise and J. Theil are employees of Xcenda GmbH, a company that received funding from Gilead Sciences to conduct this study. M. Gurrath and H.-D. Orzechowski are employees of Galapagos, former employees of Gilead Sciences, and own Gilead stock.
: Anonymized statutory health insurance data were used for this study. The use of such data is not subject to ethics committee approval in Germany. <i>Consent for publication:</i> not applicable.